Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.

ABSTRACT:

Objective

To determine the safety and efficacy of vedolizumab for the prophylaxis and treatment of gastrointestinal involvement of acute graft-versus-host disease (GVHD) (GI-aGVHD).

Methods

Literature search within PubMed, EMBASE, Web of Science, and Cochrane Library for observational studies and clinical trials that evaluated the effect of vedolizumab on GI-aGVHD was done through 17 May 2022. A bivariate and random-effect meta-analysis derived the pooled observational percentages and pooled risk ratios (RRs) from baseline of primary endpoints including overall response, complete response, mortality, and adverse events.

Results

There was a total of 122 participants in eight eligible studies, including one study on the prophylactic use of vedolizumab and seven studies

SUBMITTER: Li AC 

PROVIDER: S-EPMC9692080 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature